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Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a reported median overall 29 
survival (OS) of 3–5 years.1 Most patients relapse after first-line therapy and have a poor 30 
prognosis.1 Regulatory approval of ibrutinib has provided a much needed therapeutic option for 31 
patients with relapsed or refractory (R/R) MCL,2 with ibrutinib becoming a preferred standard of 32 
care in current guidelines.3,4 The randomized, open-label phase 3 RAY study (NCT01646021) 33 
was key in confirming the efficacy and safety of ibrutinib, with ibrutinib (N=139) showing 34 
significantly improved progression-free survival (PFS) versus temsirolimus (N=141) (primary 35 
analysis [20-month follow-up]: 14.6 vs 6.2 months, hazard ratio [HR] 0.43, 95% confidence 36 
interval [CI]: 0.32–0.58).5 Here we report extended follow-up data from the final analysis of the 37 
RAY study.  38 
At this final analysis, after an almost doubled median study follow-up of 38.7 months, 33 39 
patients (24%) in the ibrutinib group and no patients in the temsirolimus group remained on 40 
initially randomized treatment. Crossover to ibrutinib from the temsirolimus group was permitted 41 
for patients who had confirmed disease progression. Fifty-five patients in the temsirolimus group 42 
(39%) received subsequent ibrutinib (42 were included in the formal study crossover; 13 43 
received ibrutinib outside of the study). Disease progression or relapse was the most common 44 
reason for discontinuing treatment for both groups (ibrutinib, 78 patients [56%]; temsirolimus, 66 45 
patients [47%]). Fewer patients in the ibrutinib group (12 [9%]) than in the temsirolimus group 46 
(39 [28%]) discontinued treatment due to adverse events (AEs); 8 patients in each arm 47 
discontinued due to death. Other reasons for discontinuation included refusing further treatment. 48 
Median duration of exposure was longer for ibrutinib than temsirolimus (ibrutinib, 14.4 months; 49 
temsirolimus, 3.0 months), as in the primary analysis. 50 
Efficacy assessments at primary analysis by the Independent Review Committee showed high 51 
concordance with investigator assessment; at final analysis, all efficacy analyses were based on 52 
investigator assessment. With additional follow-up, median PFS remained significantly longer 53 
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for ibrutinib than temsirolimus (15.6 vs 6.2 months; HR 0.45 [95% CI: 0.35–0.60]; P<0.0001); 54 
consistent with the results of the primary analysis.5 An exploratory post hoc analysis evaluated 55 
PFS by number of prior lines of therapy received (ibrutinib, 57 [41%] 1 prior line and 82 [59%] 56 
>1 prior line; temsirolimus, 50 [35%] 1 prior line and 91 [65%] >1 prior line). Median PFS for 57 
ibrutinib was significantly longer than temsirolimus regardless of the number of prior lines of 58 
treatment, and the difference in median PFS between ibrutinib- and temsirolimus-treated 59 
patients was greatest in those who received 1 prior line of therapy versus >1 (1 prior line, 25.4 60 
vs 6.2 months, respectively, HR 0.40 [95% CI: 0.25–0.64]; >1 prior line, 12.1 vs 6.0 months 61 
respectively, HR 0.53 [95% CI: 0.38–0.73]; Figure 1a). 62 
At the time of final analysis, 77 patients (55%) in the ibrutinib group and 83 (59%) in the 63 
temsirolimus group had died, with a trend toward improved OS in the patients randomized to 64 
receive ibrutinib versus temsirolimus (30.3 vs 23.5 months, respectively; HR 0.74 [95% CI: 65 
0.54–1.02]; P=0.0621). Median OS was longer for ibrutinib than temsirolimus regardless of the 66 
extent of prior treatment. However, similar to PFS, a more pronounced OS difference was 67 
observed between ibrutinib and temsirolimus treatment in those patients who had received 1 68 
prior line of therapy (1 prior line, 42.1 vs 27.0 months respectively, HR 0.74 [95% CI: 0.43–69 
1.30]; >1 prior line, 22.1 vs 17.0 months respectively, HR 0.86 [95% CI: 0.59–1.25]; Figure 1b). 70 
Overall response rate (ORR) in the final analysis was consistent with the primary analysis (77% 71 
for ibrutinib vs 47% for temsirolimus; odds ratio 4.27 [95% CI: 2.47–7.39]; P<0.0001), with a 72 
higher proportion of patients achieving a complete response (CR) with ibrutinib (23%) than with 73 
temsirolimus (3%). ORR results for ibrutinib were similar regardless of extent of prior treatment 74 
(75% vs 78% for 1 prior line and >1 prior line, respectively). However, the CR rate was two-fold 75 
higher in patients treated with ibrutinib who received 1 prior line of therapy than those who 76 
received >1 prior line: 33% and 16%, respectively. Overall median duration of response (DOR) 77 
was 23.1 months (95% CI: 16.2–28.1) with ibrutinib and 6.3 months (95% CI: 4.7–8.6) with 78 
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temsirolimus. Patients who achieved a CR on ibrutinib had a longer median DOR than patients 79 
who achieved a partial response (PR) (35.6 [n=32] vs 12.1 months [n=75]; Figure 1c). While 80 
DOR for patients achieving CR with ibrutinib remained consistent regardless of the extent of 81 
prior treatment (35.6 [n=19] vs 32.2 months [n=13] for 1 and >1 prior line of therapy, 82 
respectively), the DOR for patients achieving PR decreased with increasing lines of prior 83 
therapy (22.3 [n=24] vs 10.0 months [n=51], respectively, for those who had received 1 vs >1 84 
prior line of therapy). Therefore, DOR for complete responders with only 1 prior line was more 85 
than three times longer than for partial responders with >1 prior line of therapy. 86 
Consistent with the primary analysis, the most common treatment-emergent AEs (TEAEs) of 87 
any grade were diarrhea (33%), fatigue (24%) and cough (23%) in the ibrutinib group, and 88 
thrombocytopenia (56%), anemia (44%) and diarrhea (31%) in the temsirolimus group. Despite 89 
longer treatment exposure in the ibrutinib group versus the temsirolimus group, the frequency of 90 
grade ≥3 TEAEs (75% vs 87%), serious AEs of any grade (57% vs 60%) and AEs leading to 91 
discontinuation (17% vs 32%) were lower in the ibrutinib group than in the temsirolimus group, 92 
respectively. The most common grade ≥3 TEAEs for both groups were hematological in nature 93 
and were less frequently reported in the ibrutinib group than the temsirolimus group, 94 
respectively: neutropenia (13% vs 17%), thrombocytopenia (9% vs 43%) and anemia (9% vs 95 
20%) (Table 1). The rate of any grade bleeding was 40% and 33% in the ibrutinib and 96 
temsirolimus groups, respectively. The rate of grade ≥3 bleeding was 9% in the ibrutinib group 97 
and 5% in the temsirolimus group, with exposure-adjusted rates being lower in the ibrutinib 98 
group (0.455 events per 100 patient-months) versus the temsirolimus group (0.785 events per 99 
100 patient-months). A higher rate of grade ≥3 atrial fibrillation was observed in the ibrutinib 100 
group (5%) versus the temsirolimus group (1%); exposure-adjusted rates were similar for both 101 
groups (0.272 events per 100 patient-months for ibrutinib; 0.221 events per 100 patient-months 102 
for temsirolimus). 103 
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With longer-term follow-up, the data support a sustained clinical benefit of ibrutinib. Median time 104 
to next treatment (TTNT) was longer for patients in the ibrutinib group versus the temsirolimus 105 
group (31. 8 vs 11.6 months; HR 0.33 [95% CI: 0.24–0.46]; P<0.0001). Moreover, median time 106 
from randomization to progression or death after subsequent therapy (PFS2) was longer for 107 
ibrutinib than temsirolimus (26.2 vs 15.4 months; HR 0.67 [95% CI: 0.50–0.90]; P=0.0079; 108 
Figure 1d).  109 
Nearly half (n=29; 46%) of 63 patients randomized to ibrutinib who received subsequent 110 
anticancer therapy on study were treated with rituximab-based chemotherapy. In these 29 111 
patients, following treatment with ibrutinib, the ORR with rituximab-based chemotherapy was 112 
41% (24% CR [n=7]; 17% PR [n=5]); response was missing or not evaluable in 11 patients. 113 
Fifteen of these 29 patients were treated specifically with bendamustine-rituximab following 114 
ibrutinib (ORR 53%; 40% CR [n=6], 13% PR [n=2]); response was missing or not evaluable in 115 
six patients. 116 
In conclusion, longer-term follow-up from the final analysis of the RAY study supports the initial 117 
report, demonstrating significant improvement in ORR and PFS with ibrutinib over temsirolimus 118 
in patients with R/R MCL. At the final analysis, OS showed a trend in favor of ibrutinib versus 119 
temsirolimus (30.3 vs 23.5 months; HR 0.74 [95% CI: 0.54–1.02], P=0.0621). In the initial 120 
analysis, number of previous lines of therapy was identified as a prognostic factor.5 With longer 121 
follow-up this was evident, with patients who had received 1 prior line of therapy benefiting the 122 
most from the use of ibrutinib. More patients were able to achieve a CR (33% vs 16%), and 123 
those achieving a PR had a longer DOR (22.3 vs 10.0 months) when using ibrutinib after 1 124 
versus >1 prior line of therapy. In ibrutinib patients with 1 prior line of therapy, this resulted in a 125 
doubling of PFS versus ibrutinib patients with >1 prior line of therapy (25.4 vs 12.1 months) and 126 
an almost 15-month improvement of OS versus temsirolimus patients with 1 prior line of therapy 127 
(42.1 vs 27.0 months). These data from the RAY study, irrespective of the number of prior lines 128 
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of therapy, compare favorably to the results from pivotal clinical trials of other single agents in 129 
R/R MCL (e.g. bortezomib, lenalidomide and temsirolimus), the use of which was associated 130 
with median PFS of 4–5 months, median OS of 13–19 months, and ORRs of 22–33%.6-9 Given 131 
that these findings support earlier use of ibrutinib in the relapsed/refractory setting, a relevant 132 
clinical question is whether patients can be successfully treated after progression on ibrutinib. 133 
Here we show that patients could be successfully rescued post ibrutinib therapy with rituximab-134 
based chemotherapy (ORR=41%), including bendamustine-rituximab (ORR=53%). Importantly, 135 
longer follow-up revealed no new late or cumulative toxicities, supporting the overall well-136 
tolerated safety profile for ibrutinib.5 The significant improvements in PFS2 provide further 137 
evidence that ibrutinib benefit is maintained beyond subsequent lines of treatment. Collectively, 138 
these results support the role of ibrutinib in the treatment of previously treated MCL. Emerging 139 
data suggest that ibrutinib may also have a role in treatment-naïve MCL,10 with multiple phase 3 140 
studies underway (e.g., ENRICH [EudraCT 2015-000832-13], SHINE [NCT01776840], and 141 
TRIANGLE [NCT02858258]). 142 
 143 
Conflicts of Interest 144 
SR has served as an advisor for Janssen, Pharmacyclics and Napp, and has received research 145 
funding from Janssen. WJ has received research funding from Janssen and Pharmacyclics. MJ 146 
has received research funding from Janssen, Celgene, Abbvie and Gilead. CR has served as 147 
an advisor for Italfarmaco, Teva, Janssen, Takeda and Roche. MT has served as an advisor 148 
and received research funding from Janssen. CJ has served as an advisor for Celgene, 149 
Janssen, Takeda, Amgen and Roche. MW-H has served as an advisor and received honoraria 150 
from Janssen. GH has served as an advisor and received honoraria from Roche, Pfizer, 151 
Janssen, CTI and Celgene, and received research support from Roche, Pfizer, Mundipharma, 152 
Final author’s draft of a paper accepted for publication in the Journal Leukemia DOI: 
”http://doi.org/10.1038/s41375-018-0023-2” 
8 
 
Celgene and CTI. CT has served as an advisor for Bayer, Celgene, Janssen and Roche, and 153 
received research funding from Roche. MD has served as an advisor and received research 154 
funding from Janssen and Pfizer, and has received honoraria from Janssen. WZ is a contractor 155 
of Janssen. TH, JG and JV are employees of Janssen and own stocks in Johnson & Johnson. 156 
FO, DC, IB-B and S-GC have no conflicts of interest to disclose. 157 
 158 
Author Contributions 159 
All authors conceived and/or designed the work that lead to this submission, acquired data 160 
and/or played an important role in interpreting the results. All authors were involved in drafting 161 
or reviewing the manuscript, and all authors approved the final version of the manuscript.  162 
 163 
Acknowledgements 164 
This study was funded by Janssen Research & Development. Writing assistance was provided 165 
by Juan Sanchez-Cortes, PhD (PAREXEL, Hackensack, NJ, USA) and Natalie Dennis 166 
(PAREXEL, Worthing, UK) and was funded by Janssen Global Services, LLC. The authors 167 
would like to thank the contribution of Mark Wildgust and Lori Parisi for their support in the long-168 
term reporting for this study. We also thank the patients who participated in this trial, their 169 
families and the investigators and coordinators at each of the clinical sites.  170 
Final author’s draft of a paper accepted for publication in the Journal Leukemia DOI: 
”http://doi.org/10.1038/s41375-018-0023-2” 
9 
 
References 171 
1. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al. 172 
Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 173 
2009; 27: 512–518. 174 
2. IMBRUVICA® [US prescribing information]. Sunnyvale, CA, USA: Pharmacyclics, LLC; 175 
Horsham, PA, USA: Janssen Biotech, Inc.; 2017. 176 
3. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in 177 
relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516. 178 
4. Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly 179 
diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for 180 
diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (suppl_4): iv62-iv71. 181 
5. Dreyling M, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M et al. 182 
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell 183 
lymphoma: an international randomised, open-label, phase 3 study. Lancet 2016; 387: 184 
770–778. 185 
6. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. 186 
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell 187 
lymphoma. J Clin Oncol. 2006; 24: 4867–4874. 188 
7. Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. 189 
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or 190 
progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J 191 
Clin Oncol. 2013; 31: 3688–3695. 192 
8. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase 193 
III study to evaluate temsirolimus compared with investigator's choice therapy for the 194 
Final author’s draft of a paper accepted for publication in the Journal Leukemia DOI: 
”http://doi.org/10.1038/s41375-018-0023-2” 
10 
 
treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009; 27: 3822–195 
3829. 196 
9. Jurczak W, Ramanathan S, Giri P, Romano A, Mocikova H, Clancy J et al. Comparison 197 
of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell 198 
lymphoma. Leuk Lymphoma. 2017 Aug 3:1-9. 199 
10. Wang ML, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR et al. 200 
Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of 201 
chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma 202 
patients: a phase II clinical trial. Blood 2016; 128: Abstract 147.  203 
Final author’s draft of a paper accepted for publication in the Journal Leukemia DOI: 
”http://doi.org/10.1038/s41375-018-0023-2” 
11 
 
Tables 204 
Table 1. Treatment-emergent adverse events (AEs) in ≥20% of patients in either treatment 205 
group 206 
Safety population Ibrutinib 
(N=139) 
Temsirolimus 
(N=139) 
AE, % Any grade Grade ≥3 Any grade Grade ≥3 
Hematological 
    
Thrombocytopenia 18.0 9.4 56.1 43.2 
Anemia 19.4 8.6 43.9 20.1 
Neutropenia 15.8 12.9 26.6 17.3 
Non-hematological 
    
Diarrhea 33.1 3.6 30.9 4.3 
Fatigue 23.7 5.0 28.8 7.2 
Cough 23.0 0.7 22.3 0.0 
Upper respiratory tract 
infection 
20.1 2.2 11.5 0.7 
Pyrexia 18.7 0.7 20.9 2.2 
Nausea 14.4 0.0 21.6 0.0 
Peripheral edema 13.7 0.0 23.7 2.2 
Epistaxis 9.4 0.7 23.7 1.4 
Stomatitis 2.9 0.0 20.9 3.6 
  207 
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Figures 208 
Figure 1. Efficacy end points in 3-year follow-up in RAY study: (a) Progression-free survival for 209 
ibrutinib and temsirolimus by prior line of therapy; (b) Overall survival for ibrutinib and 210 
temsirolimus by prior line of therapy; (c) Duration of clinical response by prior line of therapy in 211 
patients randomized to ibrutinib; (d) Time to second progression or death for ibrutinib and 212 
temsirolimus. 213 
 214 
